<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931928</url>
  </required_header>
  <id_info>
    <org_study_id>IKP275 / GBG91</org_study_id>
    <secondary_id>2016-000418-31</secondary_id>
    <nct_id>NCT03931928</nct_id>
  </id_info>
  <brief_title>Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients</brief_title>
  <acronym>TAMENDOX</acronym>
  <official_title>Genotype and Phenotype Guided Supplementation of TAMoxifen Standard Therapy With ENDOXifen in Breast Cancer Patients (TAMENDOX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Robert Bosch Gesellschaft für Medizinische Forschung mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Gesellschaft für Medizinische Forschung mbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In hormone-receptor positive breast cancer or DCIS (ductal carcinoma in situ) tamoxifen&#xD;
      remains an important treatment option for patients before menopause and those patients after&#xD;
      menopause who cannot be treated with aromatase-inhibitors. Nonetheless, a considerable amount&#xD;
      of patients suffer a relapse of their cancer while on treatment with tamoxifen. Tamoxifen is&#xD;
      a drug that is metabolized to a variety of compounds by the human liver, and the most&#xD;
      important antihormonally active metabolite is called (Z)-Endoxifen. It is known that patients&#xD;
      who have a reduced or absent activity of the drug-metabolizing enzyme CYP2D6 have lower&#xD;
      levels of (Z)-Endoxifen. Furthermore, it has been observed that patients on tamoxifen therapy&#xD;
      who have absent CYP2D6 activity are at a 2-fold increased risk for disease recurrence, and&#xD;
      patients with lower CYP2D6 compared to patients with normal CYP2D6 activity still have a&#xD;
      1.4-fold increased risk for disease recurrence.&#xD;
&#xD;
      This trial will include patients who are already on tamoxifen therapy for at least 3 months&#xD;
      and is designed to show that in patients with absent or low CYP2D6 activity, (Z)-Endoxifen&#xD;
      supplementation - that is giving (Z)-Endoxifen in addition to tamoxifen for the study period&#xD;
      of 42 days - can increase blood levels of (Z)-Endoxifen to therapeutic concentrations. It is&#xD;
      planned to included 504 patients in this blinded, randomized trial, which will have a placebo&#xD;
      group (receiving no (Z)-Endoxifen) and two intervention groups that will receive 0, 1.5 or 3&#xD;
      mg (Z)-Endoxifen depending on their CYP2D6 genetics or their (Z)-Endoxifen levels at the&#xD;
      start of the study.&#xD;
&#xD;
      The trial is not designed to evaluate outcome measures (that is recurrence or survival rates)&#xD;
      of (Z)-Endoxifen supplementation in tamoxifen treated patients, but will document the safety&#xD;
      of the combined administration of tamoxifen and (Z)-Endoxifen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Actual">May 3, 2021</completion_date>
  <primary_completion_date type="Actual">May 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(Z-)endoxifen plasma concentration &gt; 32 nM</measure>
    <time_frame>42 days (-2 days/+7 days)</time_frame>
    <description>The primary endpoint is reached if in one or both intervention groups, the proportion of patients with steady state (Z)-endoxifen plasma concentration &gt; 32 nM is greater or equal to the proportion of patients in the control group that reaches steady state (Z)-endoxifen plasma concentration of &gt; 32 nM</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in steady state (Z)-endoxifen concentration</measure>
    <time_frame>42 days (-2 days/+7 days)</time_frame>
    <description>Increase in steady state (Z)-endoxifen concentration from baseline to end of intervention (Visit 3) in patients with or without supplementation of (Z)-endoxifen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in steady state plasma concentrations of tamoxifen, desmethyltamoxifen, 4-hydroxytamoxifen and other tamoxifen metabolites following (Z-)endoxifen supplementation</measure>
    <time_frame>42 days (-2 days/+7 days)</time_frame>
    <description>Assessment of steady state plasma concentrations of tamoxifen, desmethyltamoxifen, 4-hydroxytamoxifen, and other tamoxifen metabolites following (Z)-endoxifen supplementation for 6 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])</measure>
    <time_frame>AE/SAE occurring while the subject is on IMP, or within 30 days of the patient's last dose of IMP</time_frame>
    <description>All AE/SAE occuring in the intervention period will descriptively reported</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Breast Cancer</condition>
  <condition>DCIS</condition>
  <arm_group>
    <arm_group_label>Control group (Group 1)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All patients receive Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (Z)-endoxifen dosed according to CYP2D6 &quot;genotype&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive (Z)-endoxifen dosed according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Z)-Endoxifen supplementation according to genotype</intervention_name>
    <description>Group 2: CYP2D6 genotype predicted intermediate metabolizer receive 1.5 mg, poor metabolizer receive 3 mg (Z)-Endoxifen and extensive or ultrarapid metabolizer receive 0 mg endoxifen (Placebo)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>(Z)-Endoxifen supplementation according to plasma levels</intervention_name>
    <description>Group 3: Patients will receive (Z)-endoxifen according to (Z)-endoxifen steady state plasma concentrations (phenotype) at screening (i.e. ≤ 15 nM receive 3 mg, &gt; 15 and ≤ 25 nM receive 1.5 mg (Z)-Endoxifen and &gt; 25 nM receive 0 mg (Placebo)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent obtained prior to study entry. The patient must be accessible&#xD;
             for scheduled visits and treatment.&#xD;
&#xD;
          2. Pre- and postmenopausal women with ductal carcinoma in situ (DCIS) or early stage&#xD;
             breast cancer. This includes stage I, IIA, IIB, and IIIA breast cancers.&#xD;
&#xD;
          3. ER+/PR+, ER+/PR- or ER-/PR+ receptor status. Criteria for endocrine sensitivity is ≥1%&#xD;
             ER-positive or PR-positive tumor cells on immune-histochemical staining&#xD;
&#xD;
          4. Patients on standard tamoxifen monotherapy (20 mg/d) for at least three months or&#xD;
             patients who had switched from AI to tamoxifen who are on tamoxifen treatment for at&#xD;
             least three months&#xD;
&#xD;
          5. Age ≥ 18 years&#xD;
&#xD;
          6. Body mass index of 18.5 to 35.0 kg/m2&#xD;
&#xD;
          7. The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1&#xD;
&#xD;
          8. Absolute neutrophil count greater than or equal to 1 500/µL&#xD;
&#xD;
          9. Platelets greater than or equal to 100 000/µL&#xD;
&#xD;
         10. Total bilirubin within less than or equal to 1.5 times institutional upper limit of&#xD;
             normal&#xD;
&#xD;
         11. AST/ALT less than or equal to 2.5 times institutional upper limit of normal&#xD;
&#xD;
         12. The subjects need to be either&#xD;
&#xD;
               1. of non-childbearing potential (documented postmenopausal status, defined as no&#xD;
                  menses for 12 months without an alternative medical cause, or post hysterectomy,&#xD;
                  bilateral salpingectomy or bilateral oophorectomy) or&#xD;
&#xD;
               2. of childbearing potential (WOCBP) with negative serum pregnancy test (due to the&#xD;
                  known reproduction toxicity of tamoxifen found in preclinical studies, WOCBP need&#xD;
                  to use a highly effective non-hormonal contraception. These are copper IUDs,&#xD;
                  bilateral tubal ligation, a vasectomized partner (vasectomy at least three months&#xD;
                  prior to screening) or sexual abstinence. Male or female condoms with/ without&#xD;
                  spermicide or caps, diaphragms or sponges with spermicide are associated with a&#xD;
                  failure rate &gt; 1% per year and are thus not sufficient during the intervention&#xD;
                  period.&#xD;
&#xD;
         13. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical&#xD;
             procedures to NCI CTCAE version 5.0 Grade ≤ 2 (except alopecia or other toxicities not&#xD;
             considered a safety risk for the patient at investigator's discretion)&#xD;
&#xD;
         14. Surgery and radiation therapy of the breast has to be completed upon study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects who are unable to understand written and verbal instructions&#xD;
&#xD;
          2. Locally advanced (Stadium IIIB or IIIC) or metastatic (Stage IV) breast cancer at the&#xD;
             time of surgery&#xD;
&#xD;
          3. Ongoing chemotherapy and/or treatment with trastuzumab within the last three months;&#xD;
             participation in another trial with any investigational/not-marketed drug within 3&#xD;
             months prior to baseline visit&#xD;
&#xD;
          4. Other active second malignancy&#xD;
&#xD;
          5. Invalid result of genotyping&#xD;
&#xD;
          6. Pregnancy&#xD;
&#xD;
          7. Breast feeding/lactation&#xD;
&#xD;
          8. Oral contraceptives containing estrogens and/or progesterones&#xD;
&#xD;
          9. Pathologic vaginal bleeding in pre-menopausal women or vaginal bleeding in&#xD;
             post-menopausal patients&#xD;
&#xD;
         10. Current severe acute somatic or psychiatric condition or laboratory abnormality that&#xD;
             may increase the risk associated with study participation or may interfere with the&#xD;
             interpretation of study results and, in judgement of the investigator, would make the&#xD;
             patient inappropriate for entry into this study.&#xD;
&#xD;
         11. Severe chronic cardiac or pulmonary disease (heart failure NYHA class 3 and 4), COPD&#xD;
             GOLD C or D&#xD;
&#xD;
         12. Chronic or acute renal disease with a glomerular filtration rate &lt; 60 ml/min/1.73 m2,&#xD;
             and any patient on peritoneal dialysis or hemodialysis&#xD;
&#xD;
         13. Medical history of thromboembolism (deep vein thrombosis or pulmonary embolism)&#xD;
&#xD;
         14. QTc interval &gt;0.47 sec at screening ECG&#xD;
&#xD;
         15. Concurrent treatment with strong to moderate inhibitors of CYP2D6 which may alter&#xD;
             tamoxifen metabolism (Consortium on Breast Cancer Pharmacogenomics 2008):&#xD;
&#xD;
             paroxetine, fluoxetine, bupropion, quinidine and duloxetine, diphenhydramine,&#xD;
             thioridazine, amiodarone, cimetidine, sertraline&#xD;
&#xD;
         16. Known allergies against an ingredient of the investigational product or tamoxifen&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients with ductal carcinoma in situ (DCIS) or early stage breast cancer.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Schwab, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Margarete Fischer-Bosch-Institute of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Gynäkologie und Geburtshilfe Salzgitter</name>
      <address>
        <city>Salzgitter</city>
        <state>Albert-Schweitzer-Straße 18</state>
        <zip>38226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralklinikum Suhl, Klinik für Frauenheilkunde/Geburtsmedizin, Zentrum für klinische Studien</name>
      <address>
        <city>Suhl</city>
        <state>Albert-Schweitzer-Straße 2</state>
        <zip>98527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Klinikum-Winnenden, Frauenklinik</name>
      <address>
        <city>Winnenden</city>
        <state>Am Jakobsweg 1</state>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <state>Auerbachstr. 112</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis Hildesheim, Gynäkologie</name>
      <address>
        <city>Hildesheim</city>
        <state>Bahnhofsplatz 5</state>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johanniter-Krankenhaus Stendal, Klinik für Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Stendal</city>
        <state>Bahnhofstr. 24-26</state>
        <zip>39576</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Magdeburg, Klinik für Hämatologie/Onkologie</name>
      <address>
        <city>Magdeburg</city>
        <state>Birkenallee 34</state>
        <zip>39130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen, Brustzentrum</name>
      <address>
        <city>Memmingen</city>
        <state>Bismarckstraße 23</state>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Bruderwald Bamberg, Hämatologie/Internistische Onkologie</name>
      <address>
        <city>Bamberg</city>
        <state>Buger Straße 80</state>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ am Klinikum am Bruderwald Bamberg</name>
      <address>
        <city>Bamberg</city>
        <state>Buger Straße 80</state>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Tübingen</name>
      <address>
        <city>Tübingen</city>
        <state>Calwer Straße 7</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Gifhorn, Interdisziplinäres Brustzentrum</name>
      <address>
        <city>Gifhorn</city>
        <state>Campus 6</state>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViDiA Christliche Kliniken Karlsruhe, Frauenklinik</name>
      <address>
        <city>Karlsruhe</city>
        <state>Diakonissenstr.28</state>
        <zip>76199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Quedlinburg, Frauenklinik</name>
      <address>
        <city>Quedlinburg</city>
        <state>Ditfurter Weg 24</state>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Höchst Frankfurt am Main, Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Gotenstr. 6-8</state>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Diakonie-Krankenhaus Bremen, Frauenklinik</name>
      <address>
        <city>Bremen</city>
        <state>Gröpelinger Heerstraße 406-408</state>
        <zip>28239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Gemeinschaftspraxis Brudler-Heinrich-Bangerter Augsburg</name>
      <address>
        <city>Augsburg</city>
        <state>Halderstraße 29</state>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>medius Klinik Ostfildern-Ruit, Brustzentrum</name>
      <address>
        <city>Ostfildern</city>
        <state>Hedelfingerstraße 166</state>
        <zip>73760</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Universitätsklinikum Wuppertal GmbH, Brustzentrum</name>
      <address>
        <city>Wuppertal</city>
        <state>Heusnerstraße 40</state>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Esslingen, Klinik für Frauenheilkunde, Brustzentrum</name>
      <address>
        <city>Esslingen</city>
        <state>Hirschlandstraße 97</state>
        <zip>73730</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Kliniken Sigmaringen, Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Sigmaringen</city>
        <state>Hohenzollerstr. 40</state>
        <zip>72488</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harz-Klinikum Wernigerode, Abteilung Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Wernigerode</city>
        <state>Ilsenburger Straße 15</state>
        <zip>38855</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Passau, Gynäkologische Onkologie</name>
      <address>
        <city>Passau</city>
        <state>Innstraße 76</state>
        <zip>94032</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital Dortmund, Klinische Forschung</name>
      <address>
        <city>Dortmund</city>
        <state>Johannesstraße 9-17</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Bottrop</city>
        <state>Josef-Albers-Straße 70</state>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik Mainz, Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde</name>
      <address>
        <city>Mainz</city>
        <state>Langenbeckstr. 1</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkozentrum Dresden, Fachärzte für Innere Medizin, Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Dresden</city>
        <state>Leipziger Straße 120</state>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Dr. Horst Schmidt Kliniken Wiesbaden, Klinik für Gynäkologie und gyn. Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <state>Ludwig-Erhard-Straße 100</state>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luisenkrankenhaus Düsseldorf GmbH &amp; Co. KG, Brustzentrum</name>
      <address>
        <city>Düsseldorf</city>
        <state>Luise-Rainer-Straße 6-10</state>
        <zip>40235</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital Witten, Brustzentrum</name>
      <address>
        <city>Witten</city>
        <state>Marienplatz 2</state>
        <zip>58452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe, Frauenklinik</name>
      <address>
        <city>Karlsruhe</city>
        <state>Moltkestr. 90</state>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln, Brustzentrum Köln-Holweide</name>
      <address>
        <city>Köln</city>
        <state>Neufelder Straße 32</state>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonissen-Krankenhaus Speyer, Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Speyer</city>
        <state>Paul-Egell-Straße 33</state>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg, Frauenklinik</name>
      <address>
        <city>Ludwigsburg</city>
        <state>Posilipostraße 4</state>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK Kliniken Berlin-Köpenick, Frauenklinik</name>
      <address>
        <city>Berlin Köpenick</city>
        <state>Salvador-Allende-Straße 2-8</state>
        <zip>12559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ Eggenfelden, Gynäkologische Onkologie</name>
      <address>
        <city>Eggenfelden</city>
        <state>Schellenbruckerstr. 15</state>
        <zip>84307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum am Steinenberg Reutlingen, Frauenklinik</name>
      <address>
        <city>Reutlingen</city>
        <state>Steinenbergstr. 31</state>
        <zip>72764</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SRH Wald-Klinikum Gera GmbH, Klinik für Frauenheilkunde/Geburtsmedizin</name>
      <address>
        <city>Gera</city>
        <state>Straße Des Friedens 122</state>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus Kassel gGmbH, Brustzentrum</name>
      <address>
        <city>Kassel</city>
        <state>Weinbergstr. 7</state>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MVZ am Schlosssee Gifhorn</name>
      <address>
        <city>Gifhorn</city>
        <state>Zur Allerwelle 4</state>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Gesellschaft für Medizinische Forschung mbH</investigator_affiliation>
    <investigator_full_name>Matthias Schwab</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>tamoxifen</keyword>
  <keyword>endoxifen</keyword>
  <keyword>endocrine receptor positive breast cancer</keyword>
  <keyword>adjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

